In interventional oncology, what makes RITA Medical's path particularly challenging is that the company needs to break new ground on at least a couple of levels simultaneously with its radiofrequency ablation (RFA) technology for treating solid tumors. This is not simply a case of convincing customers to substitute a next-generation device for a longstanding favorite product. The company must convince a group of physician customers-medical oncologists, who control these patients-that devices, specifically RFA technology, can play a role in oncology therapy. This when the only treatment regimens these physicians are accustomed to using are drugs and surgery.
By Stephen Levin
The phrase "missionary sell" is probably over-used in today's sales and marketing lexicon. But like all commonly used expressions, there...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
